Click Here to return To Results

 

Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis BMJ 319:1529-1533, Forbes,R.B.,et al, 1999 See this aricle in Pubmed Article Abstract The cost per QALY gained from interferon beta is high because of the high drug cost and modest clinical effect. Resources could be used more efficiently elsewhere.

Related Tags

(click to filter results - removes previous filter) controversies in neurology cost effectiveness interferon interferon beta 1-b multiple sclerosis multiple sclerosis,clinical patterns multiple sclerosis,cost of multiple sclerosis,secondary progressive multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results